

## **BrainStorm's NurOwn® Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles, California**

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Feb. 7, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that two scientific posters describing ALSFRS-R subgroup analyses and innovative micro-RNA biomarker data from the NurOwn® Phase 2 randomized double-blind placebo-controlled study will be presented as platform presentations at the American Academy of Neurology (AAN) Annual Meeting, to take place April 21-27<sup>th</sup> in Los Angeles, California.

### **Platform presentations:**

#### **"NurOwn® Phase 2 ALS Trial: ALSFRS-R Improvement is Reflected in Subscale Domains"**

Session S38: "Best of" Session: Clinical Trial Updates in Neuromuscular Disorders on April 26, 2018

**Presenter:** Merit E. Cudkowicz MD, Chief Neurology Service, Director Amyotrophic Lateral Sclerosis Clinic, Co-Director Neuromuscular Division, Massachusetts General Hospital.

#### **"Modulation of CSF miRNAs in ALS phase 2 study participants treated with MSC-NTF cells (NurOwn®)"**

Session S25: Advances in Amyotrophic Lateral Sclerosis on April 24, 2018

**Presenter:** Ralph Z. Kern MD, MHSc, Chief Operating and Medical Officer, BrainStorm Cell Therapeutics.

"Our Phase 2 placebo-controlled trial demonstrated promising clinical activity for NurOwn® in ALS, and the subgroup analyses confirm that ALSFRS-R subdomains contribute to this treatment effect. The CSF biomarker data confirms that micro-RNA released by NurOwn® may contribute to its therapeutic effect in ALS", said Ralph Kern MD, BrainStorm's Chief Operating Officer and Chief Medical Officer.

"We are pleased to have these scientific abstracts accepted at the prestigious AAN Annual Meeting, which is the largest North American Neurology conference. We are committed to continuing to understand the value that NurOwn brings to ALS through innovative clinical and scientific evaluation, and to advance the phase 3 pivotal study to bring a meaningful solution to ALS patients," commented BrainStorm's CEO Chaim Lebovits.

### **About BrainStorm Cell Therapeutics Inc.**

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 70 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo. For more information, visit the company's website at [www.brainstorm-cell.com](http://www.brainstorm-cell.com).

### **Safe-Harbor Statement**

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at <http://www.sec.gov>. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should

change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

**Contacts**

**Corporate:**

Uri Yablonka  
Chief Business Officer  
BrainStorm Cell Therapeutics Inc.  
Phone: 646-666-3188  
[uri@brainstorm-cell.com](mailto:uri@brainstorm-cell.com)

**Investors:**

Michael Rice  
LifeSci Advisors LLC  
Phone: 646-597-6979  
[mrice@lifesciadvisors.com](mailto:mrice@lifesciadvisors.com)

**Media:**

Matt Middleman, M.D.  
LifeSci Public Relations, LLC  
Phone: 646-627-8384  
[matt@lifescipublicrelations.com](mailto:matt@lifescipublicrelations.com)

View original content with multimedia:<http://www.prnewswire.com/news-releases/brainstorms-nuown-phase-2-als-clinical-trial-and-biomarker-abstracts-accepted-for-platform-presentations-at-the-70th-annual-american-academy-of-neurology-meeting-in-los-angeles-california-300594936.html>

C

SOURCE BrainStorm Cell Therapeutics Inc.

---

<https://ir.brainstorm-cell.com/2018-02-07-BrainStorms-NurOwn-R-Phase-2-ALS-Clinical-Trial-and-Biomarker-Abstracts-Accepted-for-Platform-Presentations-at-the-70th-Annual-American-Academy-of-Neurology-Meeting-in-Los-Angeles-California>